New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - lopinavir 100mg; ritonavir 25mg ((pharmacokinetic enhancer)) - film coated tablet - 100mg/25mg - active: lopinavir 100mg ritonavir 25mg ((pharmacokinetic enhancer)) excipient: colloidal silicon dioxide copovidone opadry yellow 85f32450 sodium stearyl fumarate sorbitan laurate - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - lopinavir, ritonavir - film-coated tablet - lopinavir 200 mg ritonavir 50 mg - antivirals for systemic use

United States - English - NLM (National Library of Medicine)

lannett company, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 80 mg in 1 ml - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology ( 12.4 )] . genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology ( 12.4 )] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. lopinavir and riton

Malta - English - Medicines Authority

accord healthcare limited - lopinavir; ritonavir - film-coated tablet - lopinavir 200 mg; ritonavir 50 mg - antivirals for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 100mg; ritonavir 25mg;   - film coated tablet - 100mg/25mg - active: lopinavir 100mg ritonavir 25mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 200mg; ritonavir 50mg;   - film coated tablet - 200mg/50mg - active: lopinavir 200mg ritonavir 50mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - lopinavir 200mg; ritonavir 50mg ((pharmacokinetic enhancer)) - film coated tablet - 200mg/50mg. - active: lopinavir 200mg ritonavir 50mg ((pharmacokinetic enhancer)) excipient: colloidal silicon dioxide   hyprolose hypromellose copovidone, k value 28 iron oxide yellow macrogol 3350 macrogol 400 polysorbate 80 purified talc sodium stearyl fumarate sorbitan laurate titanium dioxide - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - film coated tablets - lopinavir 100 mg; ritonavir 25 mg - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infections.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.